Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idramantone SCHEMBL12496957 | 1.00 | EPHX2 (0.52) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| Idramantone SCHEMBL3506713 | 1.00 | EPHX2 (0.52) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| Idramantone SCHEMBL12496961 | 1.00 | EPHX2 (0.52) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| Idramantone SCHEMBL3506706 | 1.00 | EPHX2 (0.52) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| Idramantone SCHEMBL3506711 | 1.00 | EPHX2 (0.52) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| SCHEMBL12765792 | 0.88 | EPHX2 (0.39) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| Idramantone SCHEMBL4719916 | 0.85 | EPHX2 (0.41) | EPHX2TSHRNPSR1HSD11B1 | |
| Adamantan-2-Ol SCHEMBL9228492 | 0.78 | CYP2C9 (0.46) | EPHX2TSHRNPSR1ALDH1A1POLB | |
| SCHEMBL482352 | 0.76 | HSD11B1 (0.33) | EPHX2HSD11B1PKM | |
| SCHEMBL13892543 | 0.76 | PKM (0.31) | EPHX2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8007 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4448107-B1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) | 2025-11-05 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| US-20250064840-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (PT) | 2025-02-27 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| EP-4448107-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | Faculdade de Farmácia da Universidade de Lisboa (PT) | 2024-10-23 | — | — | EP | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2023111829-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (PT) | 2023-06-22 | — | — | WO | claimed |
| EP-1670314-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | Sequella, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| US-6229050-B1 | VIA OXIDATION WITH OXYGEN USING A CATALYST COMPRISING AN IMIDE COMPOUND SUCH AS N-HYDROXYPHTHALIMIDE, VANADIUM COMPOUND, AND MANGANESE COMPOUND; DERIVATIVES USEFUL IN PHOTOSENSITIVE RESINS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-08 | — | — | US | claimed |